Skip to main content

FDA Approvals

FDA Approvals of Brand-Name Prescription Drugs, October 4, 2022, Through August 4, 2023

FDA Pipeline, October-December 2023

FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA

Jerm Day-Storms, PhD, MWC

FDA Approvals, Bispecific Antibodies

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

FDA Approved Xdemvy, First Treatment for Demodex Blepharitis

FDA Accelerated the Approval of Veopoz, First Drug for the Treatment of Patients With CHAPLE Disease

FDA Accelerated the Approval of Sohonos, First Drug for the Treatment of Fibrodysplasia Ossificans Progressiva

FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation

FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

Page 5 of 53
Results 41 - 50 of 527